Fujirebio Diagnostics Acquires CanAg Diagnostics

Union of Two Industry Leaders with Complementary Strengths To Benefit Global Diagnostics Field through Expanded Offerings and Distribution Channels

MALVERN, Pa. – May 31, 2006 – Fujirebio Diagnostics, Inc., a world-leader in in-vitro diagnostics, today announced that it has acquired 100% of the shares and equity-related instruments of CanAg Diagnostics AB, a leading biotechnology company based in Gothenburg, Sweden. The combination of the competencies and resources of Fujirebio Diagnostics and CanAg Diagnostics, two leaders in the field of serum tumor markers and companies with complementary strengths, will benefit the global diagnostics industry through increased customer offerings and expanded distribution channels to market. “CanAg Diagnostics possesses outstanding scientific depth and Research & Development capabilities, strong brand recognition and long-standing, positive relationships with major diagnostics companies worldwide,” said Paul Touhey, Fujirebio Diagnostics president and chief operating officer. “The combination of the two companies allows us to leverage the technical and scientific resources of both organizations to more effectively and efficiently develop new, innovative assays in the field of cancer care.” Fujirebio Diagnostics, the industry leader in tumor marker assays, specializes in the clinical development, manufacture and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis on oncology. For more than 20 years, physicians, oncologists and their patients and have relied on Fujirebio Diagnostics’ industry-trusted biomarker tests, considered the “gold standard” in the industry, to better manage cancer care. Fujirebio Diagnostics is currently developing a series of new diagnostic products to help doctors detect and/or monitor cancers associated with the bladder, lungs and ovaries. “This merger will result in greater resources for product development while creating a broader market platform for CanAg Diagnostics existing product portfolio, said Mr. Jan Sundqvist, CanAg Diagnostics president and CEO. “The merger with Fujirebio Diagnostics is recognition of the achievements of CanAg Diagnostics. The complementary synergies in R&D and clinical focus areas create stimulating possibilities for the future and we are looking forward to being a part of Fujirebio Diagnostics,” said Dr. Olle Nilsson, vice president, CSO and co-founder of CanAg Diagnostics. “The strategic aims for the Venture Capitalists when investing in CanAg Diagnostics were to build value in a leading in vitro diagnostic company with a strong product portfolio and positive cash flow. The divestment of the company marks the completion of these strategic aims,” said Mr. Anders Bergholtz, chairman CanAg Diagnostics. Investors in CanAg Diagnostics now divesting its holding in the company includes Karolinska Investment Fund, Swedish Industrial Development Fund, New Business Venture Fund, MP Bio and Founders. Contact in USA: Bob Linton Dudnyk Public Relations +1.267.532.1298 (office) +1.215.801.2771 (mobile) Contact in Sweden: Jan Sundqvist VD, CanAg Diagnostics AB +46 708 455 590 # # # Forward-Looking Statement Any statements in this press release about future expectations, plans or prospects for the Company constitute forward-looking statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Fujirebio Diagnostics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Fujirebio Diagnostics’ business.